RadNet, Inc. (RDNT) Stock Price & How to Invest

RadNet operates a network of several hundred outpatient imaging centers, mostly clustered in dense markets such as California, the Northeast, Maryland and Florida, and many of them are run in joint venture with local hospitals and health systems. The centers perform MRI, CT, PET, mammography, ultrasound and X-ray, and revenue comes primarily from commercial insurers, Medicare and Medicaid, plus a growing slice of self-pay screening. A second reporting segment, Digital Health, houses DeepHealth, the company's radiology AI and software business, which sells clinical AI tools, imaging workflow software and an enhanced breast cancer detection add-on that patients often pay for directly. The 2026 acquisition of Gleamer widened that segment's product range and installed base internationally.

The investment picture is a capital-intensive services business trying to become part software company. Scale matters in imaging because scanners are expensive, utilization drives margin, and payers negotiate rates network by network, which is why RadNet keeps buying and building centers in markets where it is already dense. Growth has been real: second quarter 2026 revenue was roughly $622.7M, up about 25% year over year, after roughly $575.6M in the first quarter, and trailing twelve month revenue reached roughly $2.27B. Earlier in the year management guided 2026 revenue growth of roughly 17% to 19% with adjusted EBITDA growth of roughly 18% to 22%. The complication is that GAAP profitability is thin to negative once depreciation, interest and stock compensation are counted (trailing net income was roughly negative $21M through June 2026), and the balance sheet carries roughly $2.18B of debt against roughly $726M of cash. The market was paying roughly $5.5B of equity value for that combination at a $69.85 share price on October 16, 2026, which prices in the Digital Health segment scaling rather than staying a rounding error.

Reimbursement is set largely by Medicare and by commercial contracts, so a rate cut or an unfavorable contract renewal flows almost straight to operating income. The business is capital intensive: scanners, buildings and IT require ongoing spending, and roughly $2.18B of debt against roughly $726M of cash at June 30, 2026 means interest expense is a permanent line item and refinancing conditions matter. Trailing twelve month net income has been slightly negative, roughly negative $21M, and the forward P/E of roughly 79 times rests on consensus 2027 EPS of about $0.89, so valuation rests on adjusted EBITDA, free cash flow and the Digital Health growth story rather than on reported earnings. Radiologist supply is tight and labor cost inflation has been a persistent pressure across the industry. Finally, the AI segment faces credible competition from imaging equipment makers and well-funded startups, and if it stays a small share of revenue the company gets valued like the capital-heavy services business it mostly still is.

8 analysts publish price targets on RDNT, averaging $94.62 against a $74.38 price as of November 2026, or +27.2%. The published targets run from $79.00 to $105.00, a narrow spread, and the ratings split 8 buy, 0 hold, 0 sell. Over the last six months there have been 2 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RDNT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on RadNet, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The site-of-care shift out of hospitals. A hospital outpatient department typically bills far more for the same MRI or CT than a freestanding center does, so insurers and employers have steadily steered volume toward independent imaging. The most optimistic published target, $105.00, assumes this works close to its best case.

The case against. Reimbursement is set largely by Medicare and by commercial contracts, so a rate cut or an unfavorable contract renewal flows almost straight to operating income. The most pessimistic target, $79.00, is roughly what RDNT is worth if this bites instead.

Read the full bull and bear case on RDNT, including what would have to change to break either one. Walnut is not an investment adviser.

No. RadNet, Inc. (RDNT) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see RadNet, Inc.'s investor relations page or your broker.

• Market cap: ~$5.5B at $69.85 (October 16, 2026)
• Revenue (TTM): ~$2.27B, against ~$2.04B for fiscal 2025
• Q2 2026 revenue: ~$622.7M, up ~25% year over year, after ~$575.6M in Q1
• Q2 2026 EPS vs estimate: ~$0.29 against a ~$0.20 consensus; Q1 was ~-$0.28 against ~-$0.19
• Net income (TTM): ~negative $21M (GAAP); operating margin ~7.9%
• Valuation multiples: ~2.4x sales, ~26x EV/EBITDA, ~79x forward EPS of ~$0.89
• Total debt / cash: ~$2.18B debt against ~$726M cash (June 30, 2026)
• Next earnings: November 5, 2026; consensus ~$0.22 EPS on ~$639M revenue

At roughly $5.5B of market value on roughly $2.27B of trailing revenue, RDNT trades near 2.4 times sales and about 26 times EV/EBITDA for a business whose GAAP bottom line is around breakeven, so the multiple is being carried by adjusted EBITDA, free cash flow growth and the Digital Health segment rather than by earnings. The second quarter beat on both revenue growth (~25%) and EPS, yet the shares are down about 1.6% in 2026 and about 9.7% over a year, sitting between a 52-week low of ~$50.82 and high of ~$85.84. Consensus looks for 2026 revenue of ~$2.51B and EPS of ~$0.51, and the November 5 report is the next check.

Other names that sit close to RDNT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get RDNT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so RDNT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RDNT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

RadNet is a scale imaging operator with a software business bolted on, so the stock tends to follow scan volumes, reimbursement rates and how quickly the AI segment compounds. As of October 16, 2026 the shares closed at $69.85, down about 1.6% in 2026 and about 9.7% over one year, after a second quarter that beat estimates; third quarter results are due November 5, 2026.

Whether RDNT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RDNT a buy or a sell?, and where the stock could go from here in the RDNT stock forecast.

For income investors, whether RDNT pays a dividend and how the payout looks is covered in does RDNT pay a dividend? And to weigh RDNT against a peer, read the full side-by-side comparisons: RDNT vs GEHC and RDNT vs SIEGY.